Adam Finn
@adamhfinn
Followers
6K
Following
76
Media
37
Statuses
2K
Paediatrician. Interested in how vaccines work & communicating that to other people.
Bristol UK
Joined February 2011
Video explainer from @guardian on the COVID-19 vaccines. What in them and how do they work?
26
19
46
🔬 Exciting New Podcast! 🎧 Join us for a captivating episode where we delve into Pediatric Infectious Diseases with Sir Andrew Pollard & Prof. Adam Finn. Discover how the pandemic affected children & gain unique insights. @adamhfinn | @OxPaediatrics Listen now!
3
2
5
Simplify manuscript submissions in academic journals! - Sign the Petition! https://t.co/gteA1xLZ4D via @UKChange
change.org
Simplify manuscript submissions in academic journals!
0
0
0
doi:
nature.com
Nature - Analysis of nearly 300,000 people finds an association between the shingles jab and a lower rate of dementia — but questions linger.
Remarkable preprint: zoster vaccine reduced dementia rates by ~20% over a 7y period. The way it was rolled out in Wales was a "natural experiment", indicating causality. Need to know if Shingrix does the same. https://t.co/r6ysk81Tk7
0
0
2
New from the UNCOVER group which made use of samples stored pre-pandemic in the Bristol Biobank. The capacity of COVID19 vaccines to induce mucosal immune responses so far has been disappointing - more attention to salivary IgA responses needed in future
nature.com
Communications Medicine - Thomas et al. test 6 ELISAs detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in...
0
1
4
First ever RSV vaccine licensed by FDA. This one is for elderly adults. After years of no options for RSV suddenly there is about to be a plethora of tools to prevent it both in infants and old people
gsk.com
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
2
10
39
Latest pre-print from the Bristol UNCOVER group - working towards a thermostable protein nanoparticle vaccine "ADDomer" against COVID19
biorxiv.org
COVID-19 continues to damage populations, communities and economies worldwide. Vaccines have reduced COVID-19-related hospitalisations and deaths, primarily in developed countries. Persisting...
1
0
0
Trends in serotype distribution and disease severity in adults hospitalised with Streptococcus pneumoniae infection in Bristol and Bath: a retrospective cohort study, 2006-2022 https://t.co/XiNKwjyNhd
#medRxiv
medrxiv.org
Background Paediatric pneumococcal conjugate vaccination (PCV) has reduced adult PCV-serotype disease: PCV7 has greater indirect effects than PCV13. Ongoing surveillance is required to evaluate...
1
3
5
Do #bivalent mRNA boosters offer equivalent protection to monovalent mRNA #COVID19 #vaccines? We try to answer this in our new #COVIDVACCINE paper from #avoncap
@BristolUncover @BristolARU @ResearchNBT @adamhfinn @AChatzilena @leondanon
https://t.co/h39XoYkQ0f
medrxiv.org
Background Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is an urgent public health priority. A precise comparison of the...
0
5
6
Do you work with bovine tuberculosis (bTB)-infected cattle? If yes @BrisPopHealth wants you to take part in the ZooTB study. Come to The White Hart, Congresbury on Monday 13 March to find out more and sign up. 👉 https://t.co/bC7eDS9rm0
#bovineTB
@n3113n @amyc_thomas
0
3
8
https://t.co/cU5TN0eO4a is now live. Understanding vaccine hesitancy. Helping “immunise” people against misinformation.
jitsuvax.info
The JITSUVAX Project was set up in response to the global spread of misinformation about vaccination. This international research consortium was funded by the EU Horizon 2020 and led by the Univers...
2
2
6
Bristol Vaccine Centre vacancy for clinical research manager. Closing date 12th October. Please forward to anyone you know who might be interested https://t.co/lLuL4qjr1k Informal enquiries to jennifer.oliver@bris.ac.uk
3
7
4
Our latest preprint, estimating effectiveness of BNT162b2 COVID-19 Vaccination in Prevention of Hospitalisations and Severe Disease in Adults with Delta & Omicron SARS-CoV-2 Infection @leondanon
@adamhfinn
@AChatzilena @rjchallen
https://t.co/ozTXdUwk7Q
1
2
7
Final peer-reviewed publication on interim analysis of Valneva phase 3 trial that supported MHRA and EMA approval now available at:
8
5
10
This paper is reported/summarised here:
news-medical.net
Researchers assess the disease severity of hospitalized adult patients with COVID-19 through the use of three different health outcomes.
0
0
2
Valneva Phase I/II trial peer review publication now out. Dose finding vs NeutABs, low reactogenicity, broad Cell mediated responses. Vaccine now licensed/authorised in EU/UK. Thanks to all sites and participants.
5
8
20
We looked carefully at lower respiratory tract disease admissions in Bristol during delta and omicron waves. Taking everything into account, omicron admissions are less severe even though patients are on average older.
medrxiv.org
Limited data exist assessing severity of disease in adults hospitalised with Omicron SARS-CoV-2 variant infections, and to what extent patient-factors, including vaccination and pre-existing disease,...
8
4
21
EMA CHMP have today recommended market authorisation of Valneva COVID19 vaccine in the EU. Another step forward for this vaccine thanks to work done by research teams in the UK and thousands of UK study participants.
valneva.com
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19...
6
2
7